review of literature on clinical pancreatology - The Pancreapedia

545. Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, RuggeriEM, Carlini P, Cognetti F. Capecitabine and celecoxib as second-line treatment <strong>of</strong> advancedpancreatic and biliary tract cancers. Oncology 2009; 76: 254-61.546. Niki T, Yamamoto Y, Tsuda M, Horita K, Hirohata S, Nishisaki H. Retrospective analysis <strong>of</strong>uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy inunresectable pancreatic cancer. Gan To Kagaku Ryoho 2009; 36: 273-8 (in Japanese).547. Sugimoto K, Okada K, Nakahira S, Okamura S, Miki H, Nakata K, Suzuki R, Yoshimura M, Uji K,Yoshida A, Tamura S. A case <strong>of</strong> metastatic pancreatic cancer after combination chemotherapy withuracil-tegafur and gemcitabine. Gan To Kagaku Ryoho 2009; 36: 321-3.548. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, HanDJ, Kim SC, Lee JL. A randomised phase II study <strong>of</strong> modified FOLFIRI.3 vs modified FOLFOX assecond-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer2009; 101: 1658-63.549. Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, KelsenDP, Schwartz GK, O'Reilly EM. A phase II study <strong>of</strong> flavopiridol (Alvocidib) in combination withdocetaxel in refractory, metastatic pancreatic cancer. Pancreatology 2009; 9: 404-9.550. Okamoto N, Inaba K, Konno H. Continuous treatment with S-1, an effective strategy for an olderadult with unresectable advanced pancreatic cancer with peritoneal dissemination – a case report.Gan To Kagaku Ryoho 2009; 36: 1187-9 (in Japanese).551. Brell JM, Matin K, Evans T, Volkin RL, Kiefer GJ, Schlesselman JJ, Dranko S, Rath L, SchmotzerA, Lenzner D, Ramanathan RK. Phase II study <strong>of</strong> docetaxel and gefitinib as second-line therapy ingemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009; 76: 270-4.552. Maemura K, Shinchi H, Noma H, Mataki Y, Kurahara H, Maeda S, Natsugoe S, Takao S.Chemoradiotherapy for locally recurrence after primary resection <strong>of</strong> biliary-pancreatic cancer. Gan ToKagaku Ryoho 2009; 36: 265-8 (in Japanese).553. Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, Ishikawa T,Matsubara H, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Yamamoto K, Kaneko T, Nieda M,Yokokawa K, Goto H. A combination therapy <strong>of</strong> gemcitabine with immunotherapy for patients withinoperable locally advanced pancreatic cancer. Pancreas 2009; 38: e69-74.554. Black JW. Reflections on some pilot trials <strong>of</strong> gastrin receptor blockade in pancreatic cancer. Eur JCancer 2009; 45: 360-4.555. Karacay H, Sharkey RM, Gold DV, Ragland DR, McBride WJ, Rossi EA, Chang CH, GoldenbergDM. Pretargeted radioimmunotherapy <strong>of</strong> pancreatic cancer xenografts: TF10-90Y-IMP-288 alone andcombined with gemcitabine. J Nucl Med 2009; 50: 2008-16.556. Eguchi H, Ishikawa O, Ohigashi H, Takahashi H, Yano M, Nishiyama K, Tomita Y, Uehara R,Takehara A, Nakamura Y, Nakagawa H. Serum REG4 level is a predictive biomarker for the responseto preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreatology 2009; 9: 791-8.557. Zhang D, Ma QY, Shen SG, Hu HT. Inhibition <strong>of</strong> pancreatic cancer cell proliferation bypropranolol occurs through apoptosis induction: the study <strong>of</strong> beta-adrenoceptor antagonist'santicancer effect in pancreatic cancer cell. Pancreas 2009; 38: 94-10.558. Ohguri T, Imada H, Yahara K, Narisada H, Morioka T, Nakano K, Korogi Y. Concurrentchemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreaticcarcinoma: initial experience. Radiat Med 2008; 26: 587-96.559. Miller RC, Iott MJ, Corsini MM. Review <strong>of</strong> adjuvant radiochemotherapy for resected pancreaticcancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys 2009;75: 364-8.